Wegovy Weight-Loss Pill Now Available for $149/Month: What You Need to Know
Novo Nordisk's blockbuster Wegovy is now available as a daily pill at a fraction of injection costs, thanks to a Trump administration deal. Here's how the new oral option compares to injections and rivals.
Wegovy’s blockbuster weight-loss drug just got a major makeover—and it could change everything for millions of Americans struggling with obesity. The pharmaceutical giant Novo Nordisk announced that the starter dose of Wegovy is now available as a daily pill instead of a weekly injection, with a price tag that’s turning heads: just $149 a month for patients paying out of pocket. This marks a seismic shift in the weight-loss drug landscape, where affordability has been the biggest barrier to access.
The Price Revolution
For years, Wegovy’s injectable form cost $349 monthly for self-pay patients, making it out of reach for many. The new pill option represents a dramatic price cut—nearly 60% cheaper than the injection for the starter dose. This shift comes courtesy of a recent deal between Novo Nordisk and the Trump administration aimed at democratizing access to GLP-1 medications.
Here’s the pricing breakdown for those paying cash directly:
- 1.5 mg starter dose (pill): $149/month
- 4 mg dose (pill): $149/month until April 15, then $199/month
- 9 mg and 25 mg doses (pill): $299/month
- Injectable version: $349/month (though new patients can get two months of the lowest doses for $199 each until March)
Insurance coverage changes the equation dramatically. Patients whose plans cover Wegovy for obesity can pay as little as $25 a month through Novo Nordisk’s savings program—whether choosing the pill or injection.
How the Pill Stacks Up Against the Injection
The FDA approved Wegovy’s oral form in late December, and clinical trials suggest it performs similarly to the injection. Both use semaglutide, the same active ingredient powering Ozempic (the diabetes version) and the original Wegovy shot.
In trials, the Wegovy pill showed average weight loss of 14% over 64 weeks compared to just 2% for placebo. The injectable version performed slightly better at 15% weight loss, but the difference is modest—suggesting the pill delivers comparable results without the needle.
What to watch for:
- Empty stomach requirement: The Wegovy pill must be taken on an empty stomach with water, and you can’t eat, drink, or take other medications for 30 minutes afterward. This is a significant drawback compared to some competitors.
- Side effects: Gastrointestinal issues like nausea and vomiting remain common. About 7% of pill trial participants stopped treatment due to side effects.
- Availability: The pill is now available through pharmacies, telehealth providers, NovoCare Pharmacy, and other locations with a prescription.
The Competitor That’s Coming
Eli Lilly isn’t sitting idle. The pharmaceutical company, which manufactures the obesity drug Zepbound and diabetes medication Mounjaro, is developing its own oral GLP-1 called orforglipron. It’s expected to receive FDA approval by summer and will also be priced at $149 for starting doses under the same Trump administration agreement.
Orforglipron has one major advantage: it can be taken anytime, with or without food. No empty stomach required. In trials, it showed 11% weight loss over 72 weeks on the highest dose—slightly lower than Wegovy’s pill but still substantial.
However, higher doses of orforglipron will cost up to $399 monthly, compared to Wegovy’s $299 for the strongest doses. The two pills haven’t been tested head-to-head, so direct comparisons remain incomplete.
Why This Matters Now
GLP-1 medications have exploded in popularity since entering the market. Reports suggest about 1 in 8 US adults currently take one of these drugs—a stunning adoption rate that reflects both their effectiveness and the obesity crisis gripping the nation.
The shift toward affordable oral options represents a watershed moment. For years, these life-changing medications were luxury goods available only to the wealthy or insured. The $149 price point—while still not free—suddenly makes them accessible to a vastly larger population. It’s the kind of move that could reshape how we treat obesity in America.
The real competition now isn’t just between Novo Nordisk and Eli Lilly. It’s about whether these companies can sustain these lower prices while maintaining profitability. If they can, we’re looking at a genuine democratization of weight-loss drugs. If they can’t, expect prices to climb once the competitive pressure eases.